openPR Logo
Press release

Global Tuberculosis Drugs Market: Deep Analysis by Production Overview and Insights 2018-2026 By Market Experts Pfizer Inc, Lupin Laboratories Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd, and Cipla Ltd

05-27-2019 04:30 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Tuberculosis Drugs

Tuberculosis Drugs

Tuberculosis is a deadly infectious disease that affects the lungs. Among diseases, tuberculosis is the second largest cause of death worldwide. Tuberculosis are broadly classified as latent tuberculosis and active tuberculosis. Globally around 10% of latent infections develop into active tuberculosis. Infections that do not show any symptoms are called latent tuberculosis. In 2015, the malady resulted in 1.8 million deaths and 10.4 million new reported cases. In 2015, in the U.S., there were 9,557 tuberculosis cases reported. Based on the statistics of Center for Disease Control and Prevention, a 1.6% increase in the number of tuberculosis cases was observed in 2015 as compared to those reported in 2014. Though there is an increase in the number of tuberculosis cases, the incidence rate per 100,000 persons has been around 3.0 since 2013. The global tuberculosis drugs market was valued at US$ 1,333.1 million in 2015 and is expected to witness a CAGR of 23.4% during the forecast period (2016 – 2024).

Ask For The Highly Informative Smaple Copy of The Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/191

Market Dynamics

Asia and Africa are the largest markets for tuberculosis drugs, as these regions have the highest prevalence of TB. There are many initiatives taken to control the TB increasing cases. The United Nations’ Millennium Development Goals have framed various strategies to reduce TB prevalence and death rates by 2015, which can be achieved by WHO’s Stop TB Strategy. According World Health Organization, in 2006, 61% out of 2.5 million new smear positive cases with DOTS, and are all the new smear cases on the year, and the treatment was successful in 85% cases. The estimated global incidence rate of tuberculosis shown decline rate by 0.6% in 2005 and 2006. In 2006, the incidence rate of tuberculosis became stable in the Europe and is declining gradually in the other WHO countries. World Health Organization has an approximation that the occurrence of tuberculosis and death rates are declining faster than the incidence rate.

With the significant increase in revenue of tuberculosis drugs market, over last decade, more than 10 chemical moiety have advanced into the clinical trial development pipeline, which include six new chemical moiety significantly and specifically developed for tuberculosis. Though there are molecules in clinical development phase, the global drug pipeline for tuberculosis is still not sufficient to address the unmet needs of treatment. Many pharmaceutical companies have produced molecules that are under clinical trials and the key challenges by any company to develop new product to treat tuberculosis and effects the tuberculosis drugs market are the needs for drugs in combination therapy, new trial strategies, studies on pediatric TB drugs, population and increased clinical trial capacity and clear regulatory guidelines.

High funding for research and development and clinical trials drugs to boost the tuberculosis drugs market

There was around US$ 6.6 billion revenue accessible for tuberculosis care and prevention in many of the low and middle-income countries in 2016, out of which 84% was from domestic sources. However, national tuberculosis program (NTPs) in low income countries linger to depend on international donors or foreign healthcare agencies to fund them approximately 90%. Investments in low income countries and middle income countries declined by US$ 2 billion to US$ 8.3 billion, which was needed in 2016. There were many enhancements needed in overall healthcare financing to curb new tuberculosis cases proportionally boosting tuberculosis drugs market. Government expenditures on healthcare in specific to tuberculosis in 2014 were less than the World Health Organization set a benchmark of at least 6% of gross domestic product in around 150 countries. Private expenditures surpassed 45% of total healthcare expenditures in tuberculosis in 46 countries, which also includes 11 of the 30 high tuberculosis burden countries.

Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/191

Presently, there are around 13 vaccine candidates in clinical development, which include trial drugs for prevention of tuberculosis infection and trial drugs for prevention of tuberculosis disease in people with Latent Tuberculosis Disease. According to WHO, at least US$ 2 billion investment is needed every year for tuberculosis research and development. In stark contrast, capital investment during 2005–2014 was reported to be US$ 0.7 billion annually. Infusion of investments in research and development would significantly improve the tuberculosis drugs market outlook.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Tuberculosis Drugs Market: Deep Analysis by Production Overview and Insights 2018-2026 By Market Experts Pfizer Inc, Lupin Laboratories Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd, and Cipla Ltd here

News-ID: 1754765 • Views: 702

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Tuberculosis

World Tuberculosis Day - Tuberculosis, the invisible pandemic
Tuberculosis is a disease that, every year, kills as many as COVID-19 does. March 24, World Tuberculosis Day, marks the anniversary of a momentous occasion - the discovery of the bacterium which causes tuberculosis in 1882. More than a hundred years after its discovery, tuberculosis is still a global health crisis. It is the leading cause of death from a single infectious disease agent, killing close to as many people per
Ocular Tuberculosis Therapeutics Market To Expand On Account Of Rising Tuberculo …
Research Nester released a report titled “Ocular Tuberculosis Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global ocular tuberculosis therapeutics market in terms of market segmentation by treatment, by end user and by region. Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model. Ocular tuberculosis is a type
Tuberculosis Diagnosis and Treatment Market
The Global Tuberculosis diagnosis and treatment market is relied upon to develop at a CAGR of 2.3 % amid 2017-2022. An irresistible illness caused by the bacterium Mycobacterium tuberculosis (MTB) is known as Tuberculosis (TB). Tuberculosis by and large influences the lungs yet can likewise influence different parts of the body. Inert tuberculosis is the sort of TB which don't have indications. Around 10% of inert contaminations advance to dynamic
Tuberculosis Testing Market | Analysis & Trends 2020
Key players in the Global Tuberculosis (TB) Testing Market, according to a report by Transparency Market Research, are Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Hain Lifescience GmbH, Hologic Inc. QIAGEN, Abbott Laboratories, Alere Inc., Epistem plc, Cepheid, bioMérieux SA, Akonni Biosystems Inc., and Sanofi. Among them, the top players namely, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, and Hain Lifescience GmbH
Global Tuberculosis Testing Market Driven by Increasing Incidences of Tuberculos …
A considerable portion of the population across geographies are suffering from a wide range of infectious diseases such as influenza, tuberculosis, AIDS, and several other bacterial and viral diseases. Tuberculosis or TB is one of the leading causes of death worldwide. Currently, organizations such as the World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND) have contributed largely towards improving global awareness regarding TB, its diagnosis, and
Tuberculosis Testing Market to Reach US$2.6 bn by 2020 owing to Increasing Tuber …
A considerable portion of the population across geographies are suffering from a wide range of infectious diseases such as influenza, tuberculosis, AIDS, and several other bacterial and viral diseases. Tuberculosis or TB is one of the leading causes of death worldwide. Currently, organizations such as the World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND) have contributed largely towards improving global awareness regarding TB, its diagnosis, and